NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
12 trialsNCT03523585 2026-02-27
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo
Phase 3 Completed
NCT02158507 2026-01-22
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
University of Alabama at Birmingham
Phase NA Completed
NCT03784014 2025-12-11
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Active not recruiting
NCT00770809 2025-08-15
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00680901 2025-08-07
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
Phase 3 Completed
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT04608409 2025-06-29
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
University of Kentucky
Phase 1 Completed
NCT01273610 2025-06-10
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT01526369 2025-05-09
TH V THL
Cancer Trials Ireland
Phase 3 Completed
NCT00490139 2025-03-21
ALTTO
Novartis
Phase 3 Completed
NCT00667251 2025-03-21
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Novartis
Phase 3 Completed